A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer

NCT ID: NCT06471205

Last Updated: 2025-05-07

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 52 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-08-02
• Study Completion Date: 2026-07-31

Brief Summary

This phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 combined with PD-1 monoclonal antibody in patients with unresectable locally advanced or recurrent metastatic triple-negative breast cancer.

Conditions

Triple-negative Breast Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BL-B01D1+PD-1 Monoclonal Antibody

Participants receive BL-B01D1+PD-1 Monoclonal Antibody as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Group Type: EXPERIMENTAL

BL-B01D1

Intervention Type: DRUG

Administration by intravenous infusion on D1 and D8, or D1 for a cycle of 3 weeks.

PD-1 Monoclonal Antibody

Intervention Type: DRUG

Administration by intravenous infusion for a cycle of 3 weeks (Q3W).

Interventions

BL-B01D1

Administration by intravenous infusion on D1 and D8, or D1 for a cycle of 3 weeks.

Intervention Type: DRUG

PD-1 Monoclonal Antibody

Administration by intravenous infusion for a cycle of 3 weeks (Q3W).

Intervention Type: DRUG

Other Intervention Names

iza-bren; izalontamab brengitecan; BMS-986507

Eligibility Criteria

Inclusion Criteria

1. Voluntarily sign the informed consent and follow the requirements of the protocol;

2. Age: ≥18 years old and ≤75 years old;

3. Expected survival time ≥3 months;

4. ECOG 0 or 1;

5. Subjects with histologically and/or cytologically confirmed, inoperable locally advanced or recurrent or metastatic triple-negative breast cancer;

6. Patients should not have received previous systemic therapy for unresectable, locally advanced, recurrent, or metastatic triple-negative breast cancer;

7. A archived tumor tissue specimen or fresh tissue specimen of the primary or metastatic lesion within 2 years must be provided;

8. Must have at least one place in accordance with RECIST v1.1 define measurable lesions;

9. No blood transfusion, no use of cell growth factors and/or platelet raising drugs within 14 days before screening, and the organ function level must meet the requirements;

10. Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by NCI-CTCAE v5.0;

11. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, the serum or urine pregnancy test must be negative, and the patient must not be lactating; All enrolled patients should take adequate barrier contraception during the entire treatment cycle and for 6 months after the end of treatment.

Exclusion Criteria

1. ADC drugs that have received topoisomerase I inhibitors as small molecule toxins;

2. Palliative radiotherapy within 2 weeks before the first dose;

3. Patients with checkpoint inhibitors prior to neoadjuvant/adjuvant chemotherapy;

4. Use of an immunomodulatory drug within 14 days before the first dose of study drug;

5. The history of severe cardiovascular and cerebrovascular diseases in the past six months was screened;

6. QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;

7. Active autoimmune and inflammatory diseases;

8. Receiving long-term systemic corticosteroid therapy, etc., before the first dose;

9. Other malignant tumors that progressed or required treatment within 5 years before the first dose;

10. Presence of: a) poorly controlled diabetes mellitus before starting study treatment; b) severe complications associated with diabetes mellitus; c) a glycated hemoglobin level of 8% or more; d) hypertension poorly controlled by two antihypertensive drugs; e) history of hypertensive crisis or hypertensive encephalopathy;

11. Present grade ≥2 radiation pneumonitis according to the RTOG/EORTC definition; Patients with current ILD;

12. Complicated with pulmonary diseases leading to clinically severe respiratory impairment;

13. 6 months prior to screening needs treatment intervention unstable thrombotic events;

14. Patients with active central nervous system metastases;

15. Patients with massive or symptomatic effusions or poorly controlled effusions;

16. Allergic history to recombinant humanized antibody or human-mouse chimeric antibody or allergic to any excipients of the test drug;

17. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation;

18. HIV antibody positive, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;

19. Serious infection within 4 weeks before the first dose of study drug; Signs of pulmonary infection or active pulmonary inflammation within 4 weeks;

20. Participated in another clinical trial within 4 weeks before the first dose;

21. Patients with superior vena cava syndrome should not be rehydrated;

22. Have a history of psychotropic substance abuse with an inability to quit or a history of severe neurological or psychiatric illness;

23. Imaging examination showed that the tumor had invaded or wrapped the large thoracic vessels;

24. Serious unhealed wound, ulcer, or fracture within 4 weeks before signing the informed consent;

25. Clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;

26. Subjects who are scheduled to receive live vaccine or receive live vaccine within 28 days before the first dose;

27. Other circumstances considered by the investigator to be inappropriate for participation in the trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jiong Wu

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Jian Zhang

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Locations

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Sa Xiao, PHD

Role: CONTACT

xiaosa@baili-pharm.com

15013238943

Facility Contacts

Jiong Wu

Role: primary

Other Identifiers

BL-B01D1-204-04

Identifier Type: -

Identifier Source: org_study_id